Clinical trials: Oligometastasis, active
Esophageal Cancer
A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer
This study aims to evaluate the efficacy and safety of bemosubabimab combined with anlotinib and radiotherapy and chemotherapy in the treatment of patients with oligometastatic esophageal cancer.
- Trial name
- NCT07455019
- Testing
- The treatment group using pembrolizumab combined with anlotinib and radiotherapy and chemotherapy
- Where
- China
- Volunteers
- 28 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Bladder Cancer, Urothelial Carcinoma (UC)
Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA
Bladder cancer is the most common type of urothelial cancer. When the disease has spread to other parts of the body (metastatic disease), the prognosis is often poor, because there are only a few effective treatment options…
- Conditions
- Bladder Cancer, Urothelial Carcinoma (UC), Oligometastasis
- Trial name
- ASTRA (NCT07413523)
- Testing
- SBRT
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- Istituto Clinico Humanitas
Prostate Cancer, Oligometastasis
Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients
Metastatic prostate cancer has traditionally been regarded as an incurable dissemination of disease, and treatment is focused on delaying progression rather than eliminating all tumor burden.
- Trial name
- OLIGOPELVIS2 (NCT03630666)
- Testing
- IADT, IADT + radiotherapy
- Where
- 16 sites in France
- Volunteers
- 256 people
- Sponsor
- Institut Cancerologie de l'Ouest
Oligometastasis, Lung Cancer
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients…
- Conditions
- Oligometastasis, Lung Cancer, Colo-rectal Cancer, Prostate Cancer
- Trial name
- ID-COMET (NCT06563388)
- Testing
- Stereotactic Ablative Radiotherapy, Best Practice
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- Roswell Park Cancer Institute
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
This phase I/II trial tests the safety and efficacy of split-course adaptive radiation therapy in combination with immunotherapy with or without chemotherapy for the treatment of patients with stage IV lung cancer or lung cancer…
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage III Lung Cancer
- Trial name
- NCT05501665
- Testing
- Biospecimen Collection, Carboplatin, Computed Tomography
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Stereotactic Body Radiation Therapy (SBRT), Oligometastasis
SMC Radiation Oncology SABR Cohort for Oligometastasis
The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer. The main questions it aims to answer are: 1.
- Conditions
- Stereotactic Body Radiation Therapy (SBRT), Oligometastasis, Oligoprogression, ctDNA
- Trial name
- SABR-OMOP (NCT07121335)
- Testing
- Stereotactic body radiotherapy (SBRT)
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Samsung Medical Center
Breast Cancer, Oligometastasis
Radical Local vs. Palliative Therapy for Breast Cancer Patientts With Ipsilateral Humerus or Sternum Oligometastasis
A Randomized, Open Label, Phase III Trial to Evaluate Radical Local Treatment versus Palliative Treatment for Breast Cancer Patients with Primary Ipsilateral Humerus or Sternum Oligometastasis
- Trial name
- BOMB (NCT04158843)
- Testing
- Radical resection, Radical radiotherapy, Palliative treatment
- Where
- 4 sites in China
- Volunteers
- 183 people
- Sponsor
- xuexin he
Oncology, Tumor Recurrence and Metastasis
Effect of Surgical Margin Width on Recurrence and Survival in Patients With Hepatic Oligometastasis of Colorectal Cancer
The main objective of this study was to evaluate the effect of surgical margin width on the prognosis of patients with hepatic oligometastasis of colorectal cancer by statistical 1-year intrahepatic recurrence-free survival rate…
- Trial name
- NCT06934018
- Testing
- Surgery and procedure
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Fudan University
Gynecologic Cancer, Skin Cancer
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
This is a randomized open-label multicentre Phase III superiority study of the effect of adding SBRT to the standard of care treatment on overall survival in patients with rare oligometastatic cancers.
- Conditions
- Gynecologic Cancer, Skin Cancer, Head and Neck Cancer, Sarcoma
- Trial name
- OligoRARE (NCT04498767)
- Testing
- Stereotactic body radiotherapy, Palliative RT
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 200 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Oligometastasis, Metastatic Cancer
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.
- Trial name
- NCT04085029
- Where
- 5 sites in United States
- Volunteers
- 300 people
- Sponsor
- Duke University
Nasopharyngeal Carcinoma
SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma
This is a multicenter, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT combined with programmed death 1 (PD-1) antibody and chemotherapy in nasopharyngeal…
- Trial name
- NCT05524168
- Testing
- SBRT, Camrelizumab, Gemcitabine
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer, Oligo-metastatic Prostate Carcinoma
MR-guided Single-fraction SBRT for Nodal Oligorecurrent Prostate Cancer (PINPOINT)
This single-arm phase 2 trial investigates whether a single high-dose radiotherapy treatment can safely treat men whose prostate cancer has come back in a small number of lymph nodes in the pelvis or abdomen after curative…
- Conditions
- Prostate Cancer, Oligo-metastatic Prostate Carcinoma, Oligometastatic Cancer, Nodal Oligorecurrent Prostate Cancer
- Trial name
- PINPOINT (NCT07635108)
- Testing
- Single-fraction SBRT
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Odense University Hospital
Prostate Cancer Metastatic, Prostate Cancer Metastatic to Bone
Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
PSMA-PET/CT or PSMA-PET/MRI are more accurate imaging modalities compared to CT/BS; in approximately 10-20% of high-risk patients diagnosed using conventional imaging PSMA-PET up-stages the disease.
- Conditions
- Prostate Cancer Metastatic, Prostate Cancer Metastatic to Bone, Prostate Cancer, Prostate Neoplasm
- Trial name
- OLIGOMET (NCT06430411)
- Testing
- Radical prostatectomy, Prostate irradiation, Surgical metastasectomy
- Volunteers
- 500 people
- Sponsor
- Medical University of Vienna
Non-small Cell Lung Cancer, Stage IV
Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC
A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy plus stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the locoregional primary tumour, in…
- Conditions
- Non-small Cell Lung Cancer, Stage IV, Oligometastasis
- Trial name
- CHESS (NCT03965468)
- Testing
- Durvalumab, Carboplatin, Paclitaxel
- Where
- 14 sites in Italy, Netherlands and 2 more
- Volunteers
- 96 people
- Sponsor
- ETOP IBCSG Partners Foundation
Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)
This phase III randomized controlled trial evaluates the efficacy of stereotactic body radiation therapy (SBRT) in oligometastatic renal cell carcinoma.
- Conditions
- Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic
- Trial name
- STROKER (NCT06726421)
- Testing
- Stereotactic body radiotherapy (SBRT), axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib
- Where
- 9 sites in China
- Volunteers
- 252 people
- Sponsor
- Sun Yat-sen University
Cervical Cancer Stage IV
A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical Cancer
Cervical cancer is one of the most malignant reproductive system tumors that threaten women's health, characterized by distinct HPV-driven carcinogenesis and immunosuppressive tumor microenvironment.
- Trial name
- NCT06998394
- Testing
- AK104 - Chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xiangbo Wan
Colorectal Neoplasms Malignant
Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.
Colorectal cancer (CRC) is the third most common cancer worldwide. Surgical resection is one of the primary treatment options for CRC; however, postoperative recurrence remains a significant clinical challenge for both the…
- Trial name
- NCT06778382
- Testing
- Oligometastasis Treatment
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shandong Cancer Hospital and Institute
Prostate Cancer, Oligometastasis
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate…
- Conditions
- Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer
- Trial name
- VA STARPORT (NCT04787744)
- Testing
- PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease
- Where
- 20 sites in United States
- Volunteers
- 378 people
- Sponsor
- VA Office of Research and Development
Breast Cancer
Local Therapy for ER/PR-positive Oligometastatic Breast Cancer
Randomized phase 2 trial to evaluate the efficacy of local therapy for oligometastasis from ER/PR-positive breast cancer. The study hypothesis is that local therapy in addition to systemic therapy improves progression-free…
- Trial name
- LARA (NCT04698252)
- Testing
- Radiotherapy, Surgery, Radiofrequency ablation
- Where
- Brazil
- Volunteers
- 74 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Breast Cancer, Oligometastasis
Metastasis-directed Therapy for Oligometastases of Breast Cancer
OLIGAMI trial is a multi-institutional, two-arm, open-label, randomized controlled phase III trial being conducted with the participation of 50 hospitals belonging to Japan Clinical Oncology Group.
- Conditions
- Breast Cancer, Oligometastasis, Metastatic Breast Cancer
- Trial name
- OLIGAMI (NCT06135714)
- Testing
- Systemic therapy for 12 weeks after primary registration, Radiation therapy (SBRT/conventional RT), Surgery
- Where
- Japan
- Volunteers
- 146 people
- Sponsor
- Tokyo Medical and Dental University